TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02469948

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Botulinum toxin type A
Description: To inject Botulinum toxin type A on the spasticity lower extremity for stroke patients by Ultrasonography direct-guidance, Electric stimulation and Surface anatomy landmark.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A
Description: To inject Botulinum toxin type A on the spasticity lower extremity for stroke patients by Ultrasonography direct-guidance, Electric stimulation and Surface anatomy landmark.
Study: NCT03531320

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D07001-softgel capsules
Description: Active Ingredient:Gemcitabine hydrochloride

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D07001-softgel capsules
Description: Active Ingredient:Gemcitabine hydrochloride
Study: NCT00988403

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fructan - 7.5
Description: Subjects will consume 7.5 grams of fructan

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fructan - 10
Description: Subjects will consume 10 grams of fructan

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fructan - 12.5
Description: Subjects will consume 12.5 grams of fructan

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fructan -- 5 grams
Description: Subjects will consume 5 grams fructan.
Study: NCT02980055

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: collagen matrix
Description: Surgical procedure for root coverage using collagen matrix

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: connective tissue graft
Description: Surgical procedure for root coverage using connective tissue graft
Study: NCT03371082

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Gan & Lee Insulin Glargine Injection
Description: Route of administration: subcutaneous injection

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Lantus®
Description: Route of administration: subcutaneous injection
Study: NCT01319266

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrocodone Bitartrate extended-release tablet
Description: Hydrocodone bitartrate extended-release oral tablet will be administered at a dose of 45 mg and dosed one time on Day 1. Subjects will also be dosed with naltrexone hydrochloride to block opioid effects.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrocodone Bitartrate extended-release tablet
Description: Hydrocodone bitartrate extended-release oral tablet will be administered at a dose of 45 mg and dosed one time on Day 1. Subjects will also be dosed with naltrexone hydrochloride to block opioid effects.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrocodone Bitartrate extended-release tablet
Description: Hydrocodone bitartrate extended-release oral tablet will be administered at a dose of 45 mg and dosed one time on Day 1. Subjects will also be dosed with naltrexone hydrochloride to block opioid effects.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrocodone Bitartrate extended-release tablet
Description: Hydrocodone bitartrate extended-release oral tablet will be administered at a dose of 45 mg and dosed one time on Day 1. Subjects will also be dosed with naltrexone hydrochloride to block opioid effects.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrocodone Bitartrate extended-release tablet
Description: Hydrocodone bitartrate extended-release oral tablet will be administered at a dose of 45 mg and dosed one time on Day 1. Subjects will also be dosed with naltrexone hydrochloride to block opioid effects.
Study: NCT01229631

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Juice plus+
Description: Subjects in active group will be supplemented with Juice plus+ capsules (3 in the morning and 3 in the evening, for 3 months)

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo non active capsules
Description: Subjects will take non-active placebo capsules (3 in the morning and 3 in the evening, for 3 months)
Study: NCT03323333

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: psychosocial counseling
Description: A problem-solving and psychosocial skill-building intervention.
Study: NCT01813474

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: olaparib
Description: tablet oral
Study: NCT04478721

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temocillin
Description: The intervention of experimental arm will be Intravenous administration of temocillin.
Study: NCT01785797

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Silicon subdural drain placement after burr hole evacuation of chronic subdural hematoma
Study: NCT03037450

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Miniinvasive corneal neurotization
Description: Neurotization of a neurotrophic cornea
Study: NCT02186210

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: prewarming
Description: recovery slope StO2
Study: NCT04478721

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Meropenem
Description: The intervention of comparator arm will be intravenous administration of meropenem.
Study: NCT00000412

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alendronate

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Calcitriol
Study: NCT04576468

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Open flap debridement
Description: Surgical intevention

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Open flap debridement
Description: Surgical intevention

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Open flap debridement
Description: Surgical intevention
Study: NCT00000412

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Alendronate
Study: NCT04576468

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Open flap debridement
Description: Surgical intevention

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: perforated membrane
Description: surgical intervention

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: perforated membrane
Description: surgical intervention

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: leucocyte - platelet rich fibrin
Description: surgical intervention

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: leucocyte - platelet rich fibrin
Description: surgical intervention
Study: NCT06393621

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: KEFPEP®
Description: Twice daily (one pack before breakfast and the other before dinner)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Twice daily (one pack before breakfast and the other before dinner)
Study: NCT01732068

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triptorelin
Description: Triptorelin 0.1 mg/1 ml solution daily from day 1 or 2 of the cycle onwards

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Corifollitropin alfa
Description: Corifollitropin alfa 150μg (single dose) on day 2 or 3 of the cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hpHMG
Description: 300IU hMG daily from day 7 following Corifollitropin alfa until the day of ovulation triggering
Study: NCT01245010

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Water
Description: Water and education will be provided

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Education
Description: Education
Study: NCT01276925

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine
Description: 7,5 mg/ml. 10 ml for the femoral nerve, 10 ml for the anterior division of the obturator nerve, 5 ml for the lateral femoral cutaneous nerve.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine
Description: 7,5 mg/ml. 10 ml for the anterior division of the obturator nerve, 5 ml for the lateral femoral cutaneous nerve.
Study: NCT00000412

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo Calcitriol
Study: NCT04157296

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy (CBT)
Description: The CBT intervention will consist of 12 weekly 60 minute sessions of the manualized therapy, adapted from the Coping Cat program, for the treatment of pediatric anxiety disorders.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive behavioral therapy (CBT)
Description: The CBT intervention will consist of 12 weekly 60 minute sessions of the manualized therapy, adapted from the Coping Cat program, for the treatment of pediatric anxiety disorders.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: computerized cognitive training (CCT)
Description: CCT intervention will consist of approximately 30 minutes of CCT games prior to each CBT session, to engage cognitive control capacity prior to receipt of CBT. The CCT games will be designed to target focused attention, response inhibition, working memory and multiple simultaneous attention to constitute a general executive function training, and activate neural systems associated with executive function/cognitive control. Difficulty of the games will be titrated individually and by session to avoid boredom and progressively activate the functional systems underlying cognitive control.
Study: NCT01276925

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound
Description: All nerve blockades will be performed with ultrasound guidance.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound
Description: All nerve blockades will be performed with ultrasound guidance.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Ultrasound
Description: All nerve blockades will be performed with ultrasound guidance.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Peripheral nerve blockade
Description: All patients will receive injections around the three nerves before surgery.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Peripheral nerve blockade
Description: All patients will receive injections around the three nerves before surgery.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Peripheral nerve blockade
Description: All patients will receive injections around the three nerves before surgery.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Saline
Description: Isotonic. 10 ml for the femoral nerve.

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Saline
Description: Isotonic. 10 ml for the femoral nerve.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Total hip arthroplasty
Description: All patients undergoes total hip arthroplasty.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Total hip arthroplasty
Description: All patients undergoes total hip arthroplasty.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Total hip arthroplasty
Description: All patients undergoes total hip arthroplasty.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: 5 mg/ml. 3 ml for spinal anaesthesia.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: 5 mg/ml. 3 ml for spinal anaesthesia.

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Bupivacaine
Description: 5 mg/ml. 3 ml for spinal anaesthesia.
Study: NCT01569438

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gefapixant
Description: 50 or 300 mg tablets for a total daily dose of 50, 100, 150, 200, 250 or 300 mg BID, orally with food for 4 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Dose matched placebo tablets, BID, orally, with food for 4 weeks
Study: NCT01207102

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abraxane
Description: Abraxane® 100 mg/m2 IV over 30 min days 1,8,15 every 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: area under curve(AUC)=2 over 15 minutes days 1,8,15 every 28 days
Study: NCT00788879

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TSSC
Description: The intervention community is exposed to the media messages of the TSSC campaign. Residents of this community also receive the lay health worker visits as well as benefit from the positive built environment changes.
Study: NCT03496792

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Limb occlusion + negative pressure
Description: In Visit 2, a cuff will be placed on the thigh of a leg that is sealed in an airtight pressure tank. After the cuff is inflated to 250 mmHg, the pressure in the tank will be reduced to -100mmHg for 2 minutes. The application of negative pressure creates a suction effect on the leg, and leads to an overall increase in pressure gradient across the blood vessel wall and induces vascular distension.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Limb occlusion + no negative pressure
Description: In Visit 2, a cuff will be placed on the thigh of a leg that is sealed in an airtight pressure tank. The cuff is inflated to 250 mmHg for 2 minutes, but the pressure in the tank is not changed.
Study: NCT02461368

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Glenohumeral triamcinolone injection by anterior approach
Description: Glenohumeral steroid injection is performed under ultrasound-guidance by anterior approach. The injection mixture was: 1 mL triamcinolone, 4 mL lidocaine, 4 mL normal saline, and 3 mL Omnipaque (Iohexol, General Electronics Healthcare).

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Glenohumeral triamcinolone injection by posterior approach
Description: Glenohumeral steroid injection is performed under ultrasound-guidance by posterior approach. The injection mixture was: 1 mL triamcinolone, 4 mL lidocaine, 4 mL normal saline, and 3 mL Omnipaque (Iohexol, General Electronics Healthcare).
Study: NCT01073306

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Investigational Vaccine for Dengue Virus Subtype 2
Description: Subcutaneous injection in upper arm of vaccine at dose of 10 plaque-forming units (PFU)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subcutaneous injection of placebo
Study: NCT01266174

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eltoprazine
Description: Comparison of eltoprazine, dosed orally, for 8 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to match eltoprazine
Study: NCT02837510

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Standard smoking cessation counseling
Description: Participants will discuss reasons for quitting, the model of smoking as a learned habit, triggers for smoking, and trigger management; receive brief training in how to manage withdrawal symptoms and relapse prevention counseling and receive the NCI Clearing the Air self-help smoking cessation booklet. The target quit date (TQD) session will be scheduled to occur up to 2 weeks following the pre-quit session. Participants will then meet with a smoking cessation counselor for a 15 minute booster counseling session. During the first week following TQD there will be two monitoring visits to closely monitor abstinence. Weekly thereafter for four weeks, participants will attend a brief booster counseling session.
Study: NCT03561259

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 131I-MIBG
Description: Subjects will receive 18 mCi/kg of 131I-MIBG administered over 1.5 to 2 hours on Day 1 either a central line or a peripheral intravenous catheter. The maximum absolute dose of 131I-MIBG is determined by institution therapeutic limits and will not exceed 1,000 mCi. Subjects with an overall response of stable disease or better as assessed by the Investigator, and who meet certain protocol predefined criteria, may receive a second 18 mCi/kg 131I-MIBG treatment no sooner than 6 weeks following the first treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 131-MIBG + Vorinostat
Description: Subjects will receive vorinostat 180 mg/m2/dose (maximum dose 400 mg) once daily by mouth, NG, or G-tube on days -1 to +12 (14 total doses) for 14 days continuously. The 131I-MIBG treatment will be administered on day 1 via either a central line or a peripheral intravenous catheter over 1.5 to 2 hours. On day 1 of therapy, vorinostat should be taken 1 hour prior to the start of the 131I-MIBG infusion. Subjects with an overall response of stable disease or better, as assessed by the Investigator and who meet certain predefined criteria, may receive a second course of 18 mCi/kg 131I-MIBG combined with vorinostat (180 mg/m2) no sooner than 6 weeks following the first therapeutic 131I-MIBG treatment.
Study: NCT02212405

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: repetitive Transcranial Magnetic Stimulation
Description: Each participant will participate in all three arms to receive sham, 1hz and 10hz rTMS as well as PET imaging.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: repetitive Transcranial Magnetic Stimulation
Description: Each participant will participate in all three arms to receive sham, 1hz and 10hz rTMS as well as PET imaging.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: repetitive Transcranial Magnetic Stimulation Sham
Description: The sham coil is built in the same helmet of the active coil. The sham coil is has a circular shape and placed perpendicular to the scalp within the same helmet. This coil produces a similar sound and scalp sensation as the real coil.
Study: NCT03177356

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: extraction,implant placement,PRF
Description: Surgical extraction of mandibular molar using periotome and forceps followed by implant placement in inter-septal bone. Then a blood sample is withdrawn from patient and placed in the centrifuge. Then Platelet-Rich fibrin is placed in the extraction socket as space filling material

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Exctraction,Implant placement,Bone graft
Description: Surgical extraction of mandibular molar using extraction forceps and periotome followed by implant placement in interseptal bone. De-proteinized bovine bone graft material is placed as space filling material
Study: NCT00982410

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: cognitive-behavioral treatment
Description: cognitive-behavioral treatment (CBT) interventions to manage pain and decrease substance use abuse/misuse

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: educational supportive group
Description: A control condition providing social support and education about pain and/or drug use.
Study: NCT04117308

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Classic information
Description: The team delivers to each patient a unique and standardized information brochure including a definition of fetal active movements, and the need to consult if the patient perceives less the movements of her fetus.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Information by detailed brochure on the fetal active movements account
Description: Delayed single and standardized explanatory card on fetal movements (definition, interests of their follow-up, technique of movements on fetuses, table to fill during the follow-up noting the number of active movements physical feelings at 3 times of the day, managing the decrease in the number of active fetal movements).
Study: NCT00710138

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Hydroxycobalamin (Vitamin B12 Depot, Nycomed Pharma)
Description: 400 µg hydroxycobalamin (Vitamin B12 Depot, Nycomed Pharma), as a single intramuscular injection

Intervention type: DIETARY_SUPPLEMENT
Group type: SHAM_COMPARATOR
Intervention: Hydroxycobalamin (Vitamin B12 Depot, Nycomed Pharma)
Description: 400 µg hydroxycobalamin (Vitamin B12 Depot, Nycomed Pharma), as a single intramuscular injection
Study: NCT00534131

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard abdominal approach for rectal excision
Description: Standard abdominal approach for rectal excision

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: APPEAR Procedure
Description: Perineal incision to reach the distal rectum
Study: NCT03492723

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Aged Garlic Extract
Description: NR

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Aged Garlic Extract
Description: NR
Study: NCT03645395

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MT-3724
Description: Experimental treatment with MT-3724 in combination with LEN therapy.
Study: NCT00534131

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Proctectomy
Description: standard rectal excision which does not preserve the anal canal
Study: NCT04501510

Intervention type: DIAGNOSTIC_TEST
Intervention: Ultrasonographic examination validation and testing
Description: X-ray imaging as well as the ultrasonographic examination of the fracture and healing process in children will be performed. The validation of an usg will be done.

Intervention type: DIAGNOSTIC_TEST
Intervention: Ultrasonographic examination validation and testing
Description: X-ray imaging as well as the ultrasonographic examination of the fracture and healing process in children will be performed. The validation of an usg will be done.
Study: NCT04159480

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Experimental - Cogito Companion
Description: Cogito Companion

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Active Control
Description: Use of MyCAP
Study: NCT01032655

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: susceptibility test guided sequential therapy
Description: susceptibility test driven sequential therapy D1- D7 Nexium ,40mg, bid Amolin, 1gm bid D8-14 Nexium ,, 40mg, bid Flagyl, 500mg, bid~plus either one of the following~1. Klaricid, 500 mg, bid~2. Cravit, 250 mg, bid~3. Tetracycline, 500 mg, bid
Study: NCT04489043

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise and healthy lifestyle recommendations
Description: In the present study, renal transplant patients with proven prediabetes will do a planned exercise programme to test the impact of this treatment on the reversibility of prediabetes. Thus, the persistance of recurrency of prediabetes assessed by an Oral Glucose Tolerant Test (OGTT) at intermediate time points (3, 6 and 9 months) will be checked in order to increase the frequency and duration of aerobic exercise and eventually to add anaerobic/resistance training.